ONC:NSD-BeiGene, Ltd. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 251.98

Change

0.00 (0.00)%

Market Cap

USD 28.70B

Volume

0.52M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict
Created with Highstock 5.0.6

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
ONC QQQ
  • QQQ
Relative Returns (From:    To: 2025-03-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+8.54 (+1.70%)

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

+2.52 (+0.38%)

USD 76.39B
ARGX argenx NV ADR

-7.07 (-1.15%)

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

+7.36 (+2.60%)

USD 31.94B
RPRX Royalty Pharma Plc

+0.05 (+0.15%)

USD 19.31B
SMMT Summit Therapeutics PLC

+0.94 (+4.76%)

USD 14.57B
UTHR United Therapeutics Corporatio..

+6.87 (+2.19%)

USD 14.37B
INCY Incyte Corporation

+0.86 (+1.39%)

USD 14.22B
MRNA Moderna Inc

+1.51 (+4.62%)

USD 13.74B
INSM Insmed Inc

-0.54 (-0.68%)

USD 13.70B

ETFs Containing ONC

S6EW:SW Ossiam STOXX® Europe 600.. 6.12 % 0.00 %

N/A

USD 0.11B
EDGE:CA Evolve Innovation Index F.. 0.00 % 0.60 %

+0.76 (+-0.05%)

CAD 0.04B
L6EW:LSE Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

-27.00 (-0.05%)

USD 0.11B
UD02:LSE UBS(Lux)Fund Solutions �.. 0.00 % 0.00 %

-12.10 (-0.05%)

USD 0.03B
S6EW:PA Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

+0.08 (+-0.05%)

USD 0.11B
UIMY:F UBS (Lux) Fund Solutions .. 0.00 % 0.00 %

-0.10 (-0.05%)

USD 0.03B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+0.06 (+-0.05%)

USD 0.02B
EDGE-U:CA Evolve Innovation Index F.. 0.00 % 0.00 %

-0.01 (-0.05%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 28.70B 99% N/A 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector